Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium

Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure

(2011) Jason P Cooper et al.   BRITISH JOURNAL OF PHARMACOLOGY

Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group

(2011) J. G. Villablanca et al.   CLINICAL CANCER RESEARCH

Identification of Dihydroceramide Desaturase as a Directin VitroTarget for Fenretinide

(2011) Mehrdad Rahmaniyan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Comparison of 123I-metaiodobenzylguanidine (MIBG) and 131I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group

(2011) Arlene Naranjo et al.   PEDIATRIC BLOOD & CANCER

Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

(2010) Suzanne Shusterman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study

(2010) Rochelle Bagatell et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer

(2009) Bryan J. Schneider et al.   INVESTIGATIONAL NEW DRUGS

Iodine-131—Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide

(2009) Melissa Rayburg et al.   PEDIATRIC BLOOD & CANCER

N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing

(2008) H. Wang et al.   MOLECULAR CANCER THERAPEUTICS